Intapiboon Porntip, Pinpathomrat Nawamin, Juthong Siriporn, Uea-Areewongsa Parichat, Ongarj Jomkwan, Siripaitoon Boonjing
Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Vaccines (Basel). 2023 Feb 24;11(3):537. doi: 10.3390/vaccines11030537.
Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce. In this study, we reported the humoral immunogenicity of an mRNA booster 90-180 days after completing heterologous CoronaVac/ChAdOx1 nCoV-19 ( = 19) or homologous ChAdOx1 nCoV-19 ( = 14) vaccination by measuring the anti-SARS-CoV-2 receptor binding domain (RBD) IgG levels at one and three months after mRNA booster vaccination. This study included 33 patients with ARDs [78.8% women; mean (SD) age: 42.9 (10.6) years]. Most patients received prednisolone (75.8%, mean [IQR] daily dose: 7.5 [5, 7.5] mg) and azathioprine (45.5%). The seropositivity rates were 100% and 92.9% in CoronaVac/ChAdOx1 and ChAdOx1/ChAdOx1, respectively. The median (IQR) anti-RBD IgG level was lower in the ChAdOx1/ChAdOx1 group than in the CoronaVac/ChAdOx1 group (1867.8 [591.6, 2548.6] vs. 3735.8 [2347.9, 5014.0] BAU/mL, = 0.061). A similar trend was significant in the third month [597.8 (735.5) vs. 1609.9 (828.4) BAU/mL, = 0.003]. Minor disease flare-ups occurred in 18.2% of the patients. Our findings demonstrated satisfactory humoral immunogenicity of mRNA vaccine boosters after a primary series, with vaccine strategies other than the mRNA platform. Notably, the vaccine-induced immunity was lower in the ChAdOx1/ChAdOx1 primary series.
在自身免疫性风湿病（ARDs）患者中，完成除mRNA疫苗之外的基础免疫接种后，关于mRNA SARS-CoV-2疫苗加强针的免疫原性数据稀缺。在本研究中，我们报告了在完成异源 CoronaVac/ChAdOx1 nCoV-19（n = 19）或同源ChAdOx1 nCoV-19（n = 14）接种后90 - 180天进行mRNA加强针接种的体液免疫原性，通过在mRNA加强针接种后1个月和3个月测量抗SARS-CoV-2受体结合域（RBD）IgG水平。本研究纳入了33例ARDs患者[女性占78.8%；平均（标准差）年龄：42.9（10.6）岁]。大多数患者接受泼尼松龙治疗（75.8%，平均[四分位间距]每日剂量：7.5[5，7.5]mg）和硫唑嘌呤治疗（45.5%）。CoronaVac/ChAdOx1组和ChAdOx1/ChAdOx1组的血清阳性率分别为100%和92.9%。ChAdOx1/ChAdOx1组的抗RBD IgG水平中位数（四分位间距）低于CoronaVac/ChAdOx1组（1867.8[591.6，2548.6]对3735.8[2347.9，5014.0]BAU/mL，P = 0.061）。在第3个月，类似趋势具有显著性[597.8（735.5）对1609.9（828.4）BAU/mL，P = 0.003]。18.2%的患者出现轻微疾病复发。我们的研究结果表明，在基础免疫接种后，使用非mRNA平台的疫苗策略时，mRNA疫苗加强针具有令人满意的体液免疫原性。值得注意的是，ChAdOx1/ChAdOx1基础免疫系列诱导的疫苗免疫力较低。
